ERBB2 and breast carcinoma: It is used in metastatic breast cancer with capecitabine and with letozole in hormone positive HER2-positive breast cancer previously treated with trastuzumab (237), and as a second line of treatment in HER2-positive breast cancer after trastuzumab failure (238, 239).